Umbra Applied Technologies Group (UTA) announced that its Biotech Division has finalized agreements that will enable the company to bring forward the greatly anticipated blood preservation treatment Propestat(TM). Propestat(TM) is the backbone of UAT's Cellgevity(TM) brand found only in the much-anticipated Blood Management System. Under Project Ichor, UAT worked closely with its sister company, Intrepid Medical Technologies Corporation to deliver the UAT BMS (Blood Management System).

With this new Blood Management System, UAT introduced a paradigm shift in blood management with an advanced, reliable and cost-efficient blood and platelet containment system design. When released, the UAT blood management system with Cellgevity(TM) powered by UAT's Propestat(TM) will be the most technologically advanced blood collection and storage system in the world. UAT's blood and platelet management system offers outstanding preservation performance with an unparalleled attention to function, ergonomics and quality.

UAT's blood management system with Cellgevity(TM) will deliver unparalleled performance preserving blood platelets up to 10 times longer than any other bag in the world. This revolutionary new Blood Management System is just that, a system of sophisticated technology working harmoniously together to document historical information on its contents and extend viability and integrity of blood products. Whole blood and whole blood products are obtained directly or indirectly through blood donation from which no constituent like red blood cells, white blood cells, plasma, or platelets, are removed.

Whole blood management has not seen much improvement as 90% of blood collected globally uses a manual process that includes record keeping, handling, and transportation. This provides significant opportunity for Umbra Applied Technologies, which is working towards the improvement of existing protocols and preservation technology.